The short version

From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.

  • Humana is the larger company, worth $52.8B, about 5.1 times Oscar Health.
  • Humana grew revenue faster over the last year (+25.7% vs -6.2%).
  • Oscar Health keeps more of each dollar of revenue as operating profit (2128.9% vs 39.6%).
  • Humana's price assumes faster free cash flow growth: about 31% a year, against -4% for Oscar Health (reverse DCF).

Side by side

The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.

MeasureHUMOSCR
Market cap$52.8B$10.4B
Share price$431.87$33.37
Revenue (last fiscal year)$5.8B$29M
Free cash flow (last fiscal year)$375M$1.1B
Revenue growth, last year+25.7%-6.2%
Revenue growth per year, last 5 fiscal years+17.5%+51.7%
Operating margin39.6%2128.9%
Net margin18.3%1861.9%
Return on equity6.1%26.8%
P/E (trailing)46.9x—
Price / free cash flow140.9x9.86x
EV / EBITDA20.6x9.58x
FCF growth the price implies31.1%-4.4%
Dividend yield0.82%—
Debt / equity1.97x4.47x
Fundamental gradeDC
Superinvestors holding it92
Insider purchases, last 12 months31

Results from SEC filings

Revenue and free cash flow by fiscal year, from each company's 10-K filings.

Humana

YearRevenueFree cash flowOp. margin
2021$3.1B$920M103.0%
2022$4.8B$3.5B79.6%
2023$4.0B$3.0B99.5%
2024$4.4B$2.4B57.8%
2025$5.8B$375M46.4%

Oscar Health

YearRevenueFree cash flowOp. margin
2021$5M-$208M-10094.2%
2022$65M$351M-908.5%
2023$21M-$298M-1103.4%
2024$21M$950M278.3%
2025$29M$1.1B-1386.2%

Where the revenue comes from

Humana · by segments, 2025

Insurance$124.6B85%
CenterWell$22.5B15%

Oscar Health

No segment breakdown reported.

Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open HUM in Investingly

Questions

Which is bigger, Humana or Oscar Health?

Humana (HUM), at $52.8B against $10.4B.

Which grows faster, HUM or OSCR?

Humana: revenue grew +25.7% over the last year, against -6.2%.

Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.